Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection

References

• Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705–714.
   PubMed Web of Science ®Google Scholar
• Kim W. The burden of hepatitis C in the United States. Hepatology. 2002;36(S1):S30S34.
   Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2013;380(9859):2095–2128.
   Web of Science ®Google Scholar
• Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):51321, 521,e1e6.
   Web of Science ®Google Scholar
• Feuerstadt P, Bunim AL, Garcia H, et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology. 2010;51(4):1137–1143.
   PubMed Web of Science ®Google Scholar
• Kattakuzhy S, Levy R, Kottilil S. Sofosbuvir for treatment of chronic hepatitis C. Hepatol Int. 2015;9(2):161–173.
   PubMed Web of Science ®Google Scholar
• Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2012;56(6):3359–3368.
   PubMed Web of Science ®Google Scholar
• Rower JE, Meissner EG, Jimmerson LC, et al. Serum and cellular ribavirin pharmacokinetic and concentration–effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015;70(8):2322–2329.
   PubMed Web of Science ®Google Scholar
• Page T, Connor JD. The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochemistry. 1990;22(4):379–383.
   PubMedGoogle Scholar
• Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35(5):1002–1009.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. New England J Med. 2013;368(1):34–44.
   PubMed Web of Science ®Google Scholar
• Jensen DM, O’Leary JG, Pockros PJ, et al., Abstract 45: Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. Hepatol. 2014;60(S1): 219A.
   Google Scholar
• Harrington PR, Fleischer R, Connelly SM, et al. Ribavirin reduces absolute lymphocyte counts in hepatitis C virus infected patients treated with interferon-free direct-acting antiviral regimens. Clin Infect Dis. 2015;61(6):974–977.
   PubMed Web of Science ®Google Scholar
• Foster GR, Pianko S, Brown A, et al. Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and HCV Genotype 2 Infection. Gastroenterology. 2015. DOI:10.1053/j.gastro.2015.07.043.
   Web of Science ®Google Scholar
• Molina J-M, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. The Lancet. 2015;385(9973):1098–1106.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. Jama. 2014;312(4):353–361.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. New England J Med. 2014;370(21):1993–2001.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–1877.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. New England J Med. 2013;368(20):1878–1887.
   PubMed Web of Science ®Google Scholar
• Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. Jama. 2013;310(8):804–811.
   PubMed Web of Science ®Google Scholar
• Nelson DR. Abstract: HCV-TARGET International Registry: Do Phase III Trials Translate into Real World? In: 15th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD); 2015 Jun 26–28; Berlin, Germany.
   Google Scholar
• Backus L, Belperio P, Shahoumian T, et al. Effectiveness of sofosbuvir‐based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 US Veterans. Aliment Pharmacol Ther. 2015;42(5):559–573.
   PubMed Web of Science ®Google Scholar
• European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199–236.
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA/IAS-USA. Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus [Internet]. [ cited 2015 Aug 31]. Available from: http://www.hcvguidelines.org.
   Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1):S45S57.
   Google Scholar
• Institute for Health Metrics and Evaluation. The Global Burden of Disease: Generating Evidence, Guiding Policy – European Union and European Free Trade Association Regional Edition. Seattle (WA): Institute for Health Metrics and Evaluation; 2013.
   Google Scholar
• Institute for Health Metrics and Evaluation. GBD 2013 Protocol. Seattle (WA): IHME; 2014.
   Google Scholar
• Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open‐label, phase 3 trial. J Viral Hepat. 2014;21(11):762–768.
   PubMed Web of Science ®Google Scholar
• Kao J-H, Ahn S-H, Chien R-N, et al. P0809: 98% SVR12 in Korean And Taiwanese patients with chronic genotype 2 HCV infection receiving 12 weeks of sofosbuvir plus ribavirin: Results from an international, multicenter phase 3 study. J Hepatol. 2015;62:S638.
   Web of Science ®Google Scholar
• Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62(5):1040–1046.
   PubMed Web of Science ®Google Scholar
• Doss W, Shiha G, Hassany M, et al. Sofosbuvir Plus Ribavirin for Treating Egyptian Patients With Hepatitis C Genotype 4. J Hepatol. 2015;63(3):581–585.
   PubMed Web of Science ®Google Scholar
• Lai CL, Wong VW, Yuen MF, et al. Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. Aliment Pharmacol Ther. 2015. DOI:10.1111/apt.13429.
   Web of Science ®Google Scholar
• Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122(4):889–896.
   PubMed Web of Science ®Google Scholar
• Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated hepatitis C virus–related graft cirrhosis after liver transplantation. Hepatology. 2000;32(4):852–858.
   PubMed Web of Science ®Google Scholar
• Garcia‐Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35(3):680–687.
   PubMed Web of Science ®Google Scholar
• Simmons B, Saleem J, Heath K, et al. Long-term treatment outcomes of patients infected with Hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a Sustained Virological Response. Clin Infect Dis. 2015;61(5):730–740.
   PubMed Web of Science ®Google Scholar
• Van Der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama. 2012;308(24):2584–2593.
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677–684.
   PubMed Web of Science ®Google Scholar
• Mathias A, Cornpropst M, Clemons D, et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers. Hepatology. 2012;56(Suppl S1):1063A1064A.
   Google Scholar
• Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148(1):100–107, e1.
   PubMed Web of Science ®Google Scholar
• Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61(5):1485–1494.
   PubMed Web of Science ®Google Scholar
• Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108–117.
   PubMed Web of Science ®Google Scholar
• Saab S, Jimenez M, Bau S, et al. Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis. Clin Transplant. 2015;29(9):813–819.
   Web of Science ®Google Scholar
• Reddy K, Lim JK, Kuo A, et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: report from HCV-TARGET. J Hepatol. 2015;62(suppl 2):S193.
   Google Scholar
• Gane EJ, Robson RA, Bonacini M, et al. Abstract 667: Safety, anti-viral efficacy and pharmacokinetics (PK) of sofosbuvir (SOF) in patients with severe renal impairment. Hepatol. 2014;60(S1): 667A.
   Google Scholar
• Saxena V, Koraishy FM, Sise M, et al., LP08: Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target. J Hepatol. 2015;62:S267.
   Google Scholar
• Svarovskaia ES, Dvory‐Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1–6 hepatitis C virus–infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59(12):1666–1674.
   PubMed Web of Science ®Google Scholar
• Group GBoHCW. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44(1):20–29.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences I. Chronic Hepatitis C Treatment Expansion: Generic Manufacturing for Developing Countries. 2015 Available from: http://www.gilead.com/~/media/files/pdfs/other/hcvgenericagreementfactsheet.pdf?la=en.
   Google Scholar
• Lim SG, Dan YY. A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean J Intern Med. 2015;30(4):423–433.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New England J Med. 2014;370(16):1483–1493.
   PubMed Web of Science ®Google Scholar
• Wilson E, Kattakuzhy S, Sims Z, et al. High efficacy of retreatment with ledipasvir and sofosbuvir in HCV patients who failed initial short course therapy with combination DAA regimens (NIH SYNERGY trial). Clin Infect Dis. 2015. DOI:10.1093/cid/civ874.
   Google Scholar